View in EDS HTML Full Text PDF Full Text

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).

Saved in:
Bibliographic Details
Title: EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
Authors: Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Castro CD; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Ricaurte LM; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Cardona AF; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad El Bosque, Bogotá, Colombia. andres.cardona@clinicadelcountry.com., Rojas L; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Clinical Oncology Department, Clínica Colsanitas, Bogotá, Colombia., Zatarain-Barrón ZL; Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico., Wills B; Internal Medicine Department, Johns Hopkins University, Baltimore, MD, USA., Reguart N; Medical Oncology Department, Hospital Clinic, Barcelona, Spain., Carranza H; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia., Vargas C; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia., Otero J; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia., Corrales L; Clinical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica., Martín C; Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina., Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Rodriguez J; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Avila J; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Bravo M; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Pino LE; Medical Oncology Group, Fundación Santa Fe de Bogotá, Bogotá, Colombia., Rosell R; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain., Arrieta O; Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Corporate Authors: Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)
Source: Targeted oncology [Target Oncol] 2018 Oct; Vol. 13 (5), pp. 621-629.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 30284706
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ruiz-Patiño+A%22">Ruiz-Patiño A</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Castro+CD%22">Castro CD</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Ricaurte+LM%22">Ricaurte LM</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Cardona+AF%22">Cardona AF</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad El Bosque, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.<br /><searchLink fieldCode="AU" term="%22Rojas+L%22">Rojas L</searchLink>; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Clinical Oncology Department, Clínica Colsanitas, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Zatarain-Barrón+ZL%22">Zatarain-Barrón ZL</searchLink>; Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.<br /><searchLink fieldCode="AU" term="%22Wills+B%22">Wills B</searchLink>; Internal Medicine Department, Johns Hopkins University, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Reguart+N%22">Reguart N</searchLink>; Medical Oncology Department, Hospital Clinic, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Carranza+H%22">Carranza H</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Vargas+C%22">Vargas C</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Otero+J%22">Otero J</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Corrales+L%22">Corrales L</searchLink>; Clinical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica.<br /><searchLink fieldCode="AU" term="%22Martín+C%22">Martín C</searchLink>; Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Archila+P%22">Archila P</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Rodriguez+J%22">Rodriguez J</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Avila+J%22">Avila J</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Bravo+M%22">Bravo M</searchLink>; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Pino+LE%22">Pino LE</searchLink>; Medical Oncology Group, Fundación Santa Fe de Bogotá, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Rosell+R%22">Rosell R</searchLink>; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Arrieta+O%22">Arrieta O</searchLink>; Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Latin-American+Consortium+for+the+Investigation+of+Lung+Cancer+%28CLICaP%29%22">Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101270595%22">Targeted oncology</searchLink> [Target Oncol] 2018 Oct; Vol. 13 (5), pp. 621-629.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+France%22">Springer-Verlag France </searchLink><i>Country of Publication: </i>France <i>NLM ID: </i>101270595 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1776-260X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217762596%22">17762596 </searchLink><i>NLM ISO Abbreviation: </i>Target Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30284706
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11523-018-0594-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 621
    Titles:
      – TitleFull: EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ruiz-Patiño A
      – PersonEntity:
          Name:
            NameFull: Castro CD
      – PersonEntity:
          Name:
            NameFull: Ricaurte LM
      – PersonEntity:
          Name:
            NameFull: Cardona AF
      – PersonEntity:
          Name:
            NameFull: Rojas L
      – PersonEntity:
          Name:
            NameFull: Zatarain-Barrón ZL
      – PersonEntity:
          Name:
            NameFull: Wills B
      – PersonEntity:
          Name:
            NameFull: Reguart N
      – PersonEntity:
          Name:
            NameFull: Carranza H
      – PersonEntity:
          Name:
            NameFull: Vargas C
      – PersonEntity:
          Name:
            NameFull: Otero J
      – PersonEntity:
          Name:
            NameFull: Corrales L
      – PersonEntity:
          Name:
            NameFull: Martín C
      – PersonEntity:
          Name:
            NameFull: Archila P
      – PersonEntity:
          Name:
            NameFull: Rodriguez J
      – PersonEntity:
          Name:
            NameFull: Avila J
      – PersonEntity:
          Name:
            NameFull: Bravo M
      – PersonEntity:
          Name:
            NameFull: Pino LE
      – PersonEntity:
          Name:
            NameFull: Rosell R
      – PersonEntity:
          Name:
            NameFull: Arrieta O
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2018 Oct
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 1776-260X
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Targeted oncology
              Type: main
ResultId 1